Shingles Vaccine Linked to Reduced Dementia Risk
Oxford University study finds Shingrix vaccine delays dementia onset by up to nine months, offering new hope for older adults.
Overview
- Research shows a 17% lower risk of dementia in those vaccinated with Shingrix compared to Zostavax.
- The study observed over 200,000 people aged 65 and older for six years.
- Women experienced greater benefits, with a 22% reduction in dementia risk.
- Experts call for further research to confirm findings and understand mechanisms.
- Shingrix is currently offered to individuals aged 70-79 and those with weakened immune systems.